Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Share-based Compensation (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Share-based Compensation for 3 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 8.01% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, down 85.67% year-over-year, with the annual reading at $11.1 million for FY2025, 80.97% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.7 million at Inhibrx Biosciences, down from $2.8 million in the prior quarter.
  • The five-year high for Share-based Compensation was $46.2 million in Q2 2024, with the low at $2.4 million in Q1 2025.
  • Average Share-based Compensation over 3 years is $9.6 million, with a median of $4.7 million recorded in 2024.
  • Peak annual rise in Share-based Compensation hit 8.01% in 2025, while the deepest fall reached 94.0% in 2025.
  • Over 3 years, Share-based Compensation stood at $6.4 million in 2023, then plummeted by 53.6% to $3.0 million in 2024, then decreased by 8.01% to $2.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.7 million, $2.8 million, and $2.4 million for Q4 2025, Q2 2025, and Q1 2025 respectively.